Investor Relations LatestPress Releases Oct 26, 2022 Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays Oct 13, 2022 Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update Oct 12, 2022 Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium btn News IR View All RecentEvents Oct 13, 2022 13 Oct 2022 at 8:30 AM EDT Third-Quarter Fiscal 2022 Financial Results Conference Call Listen to Webcast Sep 28, 2022 28 Sep 2022 at 9:00 AM EDT Cantor Oncology, Hematology & HemeOnc Conference Aug 10, 2022 10 Aug 2022 at 1:00 PM EDT Canaccord Genuity 42nd Annual Growth Conference Listen to webcast btn Events View All Financial InformationLatest Earnings Show all Q3 2022 Financial Statement 871 KB MD&A 397.9 KB btn QRs View More PresentationsInvestor Presentation Download PDF
Oct 26, 2022 Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays
Oct 13, 2022 Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
Oct 12, 2022 Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium
Oct 13, 2022 13 Oct 2022 at 8:30 AM EDT Third-Quarter Fiscal 2022 Financial Results Conference Call Listen to Webcast
Aug 10, 2022 10 Aug 2022 at 1:00 PM EDT Canaccord Genuity 42nd Annual Growth Conference Listen to webcast